Status:
COMPLETED
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Lead Sponsor:
Celgene
Conditions:
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Detailed Description
This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymph...
Eligibility Criteria
Inclusion
- Histological confirmation of diagnosis at last relapse
- Adequate organ function
- Adequate vascular access for leukapheresis procedure
Exclusion
- Prior history of malignancies, other than aggressive relapsed/refractory Non-Hodgkin Lymphoma, unless the participant has been in remission for ≥ 2 years with the exception of non-invasive malignancies
- Received previous CD19-targeted therapy
- Progressive vascular tumor invasion, thrombosis, or embolism
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
June 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT03484702
Start Date
June 5 2018
End Date
December 15 2023
Last Update
December 27 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 101
Vienna, Austria, 1090
2
Local Institution - 351
Ghent, Belgium, 9000
3
Local Institution - 551
Helsinki, Finland, 00029
4
Local Institution - 202
Lille, France, 59037